Defibrotide
DEFITELIO
- Dosage form
- Tablet
- Available strengths
- 200 mg/2.5 mL (80 mg/mL)
- Drug class
- Profibrinolytic agent (oligonucleotide)
- Common brand
- DEFITELIO
Clinical overview. Defibrotide (DEFITELIO) is an intravenous profibrinolytic medication used to treat severe hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome, following stem-cell transplantation in both adults and children. It is given as a continuous cycle of infusions every 6 hours for at least 21 days under specialist supervision. Its main risk is bleeding, so it cannot be combined with anticoagulant or clot-dissolving medications and requires close monitoring throughout treatment.
Indication
Common therapeutic uses
- Defibrotide is used to treat adult and pediatric patients with severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), occurring after hematopoietic stem-cell transplantation (HSCT).
- Defibrotide must be prescribed and administered by specialized physicians experienced in managing complications of HSCT.
Pregnancy
Risk assessment and monitoring considerations
- Defibrotide use during pregnancy is not recommended, as there are no available human data.
- Animal studies in pregnant rats and rabbits showed a high rate of hemorrhagic pregnancy loss with defibrotide.
- Effective contraception is required for both male and female patients during treatment and for one week after stopping defibrotide.
Breastfeeding
Infant exposure considerations
- Breastfeeding is not recommended during treatment with defibrotide.
- There is no information on whether defibrotide passes into human milk, but because of the potential for serious adverse reactions, including bleeding, in a breastfed infant, caution is advised.
Geriatrics
Dosing and tolerability considerations
- The safety and effectiveness of defibrotide have not been established in patients over 65 years of age, as clinical trials did not include enough older patients to determine whether they respond differently.
Pediatrics
Use in children and adolescents
- Defibrotide's safety and effectiveness have been established in pediatric patients older than 1 month of age with severe hepatic VOD following HSCT.
- Use in children younger than 1 month is not recommended, as no clinical data are available in this age group.
- The frequency, nature, and severity of side effects in children were similar to those seen in adults.
Dosage & Administration
Practical dosing and administration
- The recommended dose of defibrotide is 25 mg/kg/day, given as 6.25 mg/kg every 6 hours as a 2-hour intravenous infusion.
- Dosing is based on the patient's body weight measured before the pre-transplant conditioning regimen for HSCT.
- Treatment is given for a minimum of 21 days; if symptoms of VOD have not resolved by then, treatment continues until resolution.
- No dose adjustment is needed for renal impairment, including patients on hemodialysis.
- No dose adjustment is needed for hepatic impairment.
- No dose adjustment is needed for pediatric patients.
- Before starting treatment, confirm the patient is not experiencing clinically significant bleeding and is hemodynamically stable on no more than one blood pressure-supporting medication.
- Defibrotide must not be co-administered with other intravenous drugs through the same line, and the line should be flushed before and after infusion.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- No specific antidote exists for defibrotide overdose.
- Defibrotide is not cleared by dialysis.
- The monograph does not describe specific overdose symptoms for defibrotide; management relies on general supportive care.
Common side effects
Frequently reported tolerability concerns
- Low blood pressure (hypotension) may occur.
- Diarrhea may occur.
- Vomiting may occur.
- Nausea may occur.
- Nosebleeds (epistaxis) may occur.
- Bruising (ecchymosis) may occur.
- Blood in the urine (hematuria) may occur.
- Gastrointestinal bleeding may occur.
- Abnormal blood clotting (coagulopathy) may occur.
- Catheter site bleeding may occur.
- Small red skin spots from bleeding (petechiae) may occur.
- Itching (pruritus) may occur.
- Rash may occur.
- Fever or chills may occur shortly after an infusion.
- Flushing may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Serious bleeding (hemorrhage) is the main safety concern with defibrotide and can occur at any body site.
- Bleeding into the lungs (pulmonary alveolar hemorrhage) may occur and can be life-threatening.
- Bleeding into the brain (cerebral or intracranial hemorrhage) may occur.
- Severe allergic (anaphylactic) reactions have been reported, including in patients previously treated with defibrotide.
- Multi-organ failure may occur, particularly in patients with severe underlying VOD.
- Spinal or subdural bleeding (hematoma) has been reported.
- Abnormal blood clotting test results (elevated INR) have been reported.
- Seek urgent medical attention for unusual bleeding or bruising, blood in urine or stool, coughing up blood, sudden severe headache, or signs of an allergic reaction such as swelling or difficulty breathing.
Use with caution
Situations requiring closer assessment
- Use with caution in patients receiving antiplatelet therapy, which requires careful monitoring during defibrotide treatment.
- Discontinue defibrotide temporarily before surgery or invasive procedures, stopping the infusion at least 2 hours beforehand, and resume once the bleeding risk from the procedure has passed.
- Monitor all patients closely for signs and symptoms of bleeding throughout treatment.
- Do not start defibrotide in patients who have active or clinically significant bleeding.
- Confirm hemodynamic stability, with the patient on no more than one vasopressor, before starting treatment.
- Monitor patients with a history of hypersensitivity to defibrotide closely for severe reactions if re-exposed.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients receiving concomitant systemic anticoagulant or fibrinolytic (clot-dissolving) therapy.
- Contraindicated in patients with known hypersensitivity to defibrotide sodium or to any ingredient in the formulation.
Drug interactions
Clinically relevant combinations
- Concomitant use of defibrotide with anticoagulant or fibrinolytic drugs, such as heparin or alteplase, is contraindicated because of an increased risk of bleeding.
- Defibrotide may enhance the blood-thinning effects of heparin and alteplase, based on animal and human plasma studies.
- Systemic anticoagulant or fibrinolytic therapy should be stopped before starting defibrotide, and starting defibrotide may need to be delayed until the effects of the prior therapy have worn off.
- Defibrotide does not significantly induce or inhibit major drug-metabolizing enzymes or transporters, so pharmacokinetic interactions with other drug classes are unlikely.
Food interactions
Meal-related administration
- No specific interactions between defibrotide and food have been established.
Time of administration
Practical scheduling
- Defibrotide is given as a scheduled intravenous infusion in a hospital setting, every 6 hours around the clock, rather than at a specific time relative to meals.
Storage
Product handling
- Store unopened vials at 20°C to 25°C, with excursions permitted between 15°C and 30°C; do not freeze.
- Once diluted, the solution should be used within 24 hours if refrigerated at 2°C to 8°C, unless prepared under controlled aseptic conditions.
Patient take-away
Key counselling points for a quick closing summary
- Defibrotide is an intravenous medication used in the hospital to treat severe veno-occlusive disease of the liver after a stem-cell transplant.
- The main risk with defibrotide is bleeding, so you will be closely monitored for signs of bruising, blood in urine or stool, or unusual bleeding during treatment.
- Tell your care team right away about any unusual bleeding, severe headache, coughing up blood, or signs of an allergic reaction.
- Defibrotide cannot be given together with blood-thinning or clot-dissolving medications.
- Treatment is typically continued for at least 21 days or until your veno-occlusive disease symptoms resolve.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.